,
`‘
`
`t
`
`ct
`
`(e
`
`Volume25 AbstractSupplement August/September2004 ISSN0195-668X
`
`=
`
`ae
`
`‘y
`
`EUROPEAN
`SOCIETY OF
`CARDIOLOGY
`
`f
`
`f
`
`ESC Congress 2004
`28 August - 1 September
`Munich, Germany
`
`oiaeiad
`
`ys
`ay
`
`Editor-in-Chief: Frans Van de Werf
`
`27709704
`EUROPEAN HEART JOURNAL.
`
`BOSTONSPA
`aay
`
`:
`|
`
`|
`
`| ee INTAI IMM
`09.lune 25(2004)Suppl
`Efe AGS)
`HED supe}
`
`nt.
`
`
`
`Liquidia's Exhibit 1091
`Page 1
`
`Liquidia's Exhibit 1091
`Page 1
`
`

`

`European Heart Journal (2004) 25 (Abstract Supplement), xi-xvi
`
`
`Contents
`
`
`
`Page
`Programme number(P = poster)
`ili
`Abstract Selection ...... 0000 cece cee EERE EEE EEE EEE EEE EEE EEE E TEE E EEE EE EEE EEE EEE
`Abstract Review Committee .........6.. 00 ceceEEE EEE EEE EEE EEE EEE Vil
`ADStractS ...0.ccccccrevoueessseueeteneneeeneresereeseateeenedtsae ees eteueaaae esse reneernee caterer ertager seers cgar esses
`1
`
`Day 2 — Sunday 29 August 2004
`3
`Trends andrisk factors in cardiovascular disease. ........ 6. eseeee rete ener teen eee e eres ences
`117-122
`4
`Risk factors managementin prevention.......... see ee sence e teen e etter teeter essere eee reece
`123-128
`6
`Predictive factors in dilated cardiomyopathy ....... 0... ccs cree eee eee eee ene ten eer e renee ete e neers eres
`129-134
`7
`New applicationsof strain and strain rate imaging ........+.s es seeee seers nett renter esses sists ee eee eee sss
`135-140
`9
`From mice to men: lessons in myocardial protection and hypertrophy......-+++++ sees reese terse eee ttt e eee es
`149-154
`10
`Impact of nonsurgical treatment and physiological stress on the GUCH-heart ......+ +2000 s sees sees teenies
`155-160
`12
`Vascular growth and collateral vessels: opportunities and drawbacks. ..... cece eee eee eect tence tenets
`161-166
`13
`Drug eluting stent in complex lesion subsets ........-.- 1+ sseee eens eee ee ester neces nese sees sees sees eee
`176-181
`15
`Genevariants in hypertension, coronary artery disease and dilated cardiomyopathy ............e eee sees eee eee
`182-187
`16
`Markers of severity in hypertrophic cardiomyopathy ........-..0ese cnet eee ener enter tn nesses sees s ness sess
`188-193
`18
`How toperfect coronary artery bypass grafting? 0... cece net nen ne een e reese es
`199-204
`19
`Intravascular ultrasound and plaque characterisation ..........- see seer eee e etree erent enn te een e recess
`209-214
`Epidemiology andtreatment of pulmonary arterial hypertension .... 0.00... eee eee ee erent ees 21
`215-220
`Revisiting the electrocardiogram and electrophysiologic markers of arrhythmic events ........-+++ssereeeere eee
`22
`221-226
`Nursing aspects of acute cardiac Care... . 6.66. ieee eee cere eee eer tne ree ee eee ee eee
`24
`229-234
`Follow-up in the pacemaker and implantable cardioverter-defibrillator Era: old and new issueS........+++eeeeeees
`25
`244-249
`Threatening complications with sophisticated CEVICES oo cee cece ee reenter een ete n ene e nee een ee aeeen tes
`21)
`250-255
`New risk markers of sudden death after acute myocardial infarction ..... 02. e cece cence eee eee eee eens = 28
`256-261
`Inotropic intervention: new mechamisms..........s0eeee reese eset etter teeter n eee nese eee eee ee 30
`275-280
`Muscle wasting and cachexia in heartfailure: ready for intervention... 2.0.6... cece e teen eet nen enee
`31
`281-286
`Percutaneous coronary intervention and beyond for §T-elevation acute myocardial infarction ..........++.+++-++-
`33
`304-309
`Ilb or notto be in acute myocardial infarction? ..........0.seeeee eee etree e eres ener eres
`34
`310-315
`P356-P361 Moderated e-Posters I: Cardiac dysfunction: new insights .......--+ +--+. seerreeee eres esses seers sees ees sess ss
`36
`P362—-P377
`Atherosclerosis I — Basic Science .......- eee cece teeter nnn nenteee 37
`P378-P384
`Nuclear cardiology/Magnetic resonance imaging and cardiac radiology ...... 6. c ect e eect e eee ee teen eee ee
`41
`P385-P386
`Computers in cardiology ...... 1... .e se ee ee ee eee teen e renee eee eee eeeeee 43
`P387-P401
` Echocardiography/Doppler....... 26... 0s eee eee eeeen EEE EEE EEE 44
`P402-P417
`Atherosclerosis I — Basic Science ..... 2.6... sere eee eee etree tenner etter ree eee ees
`48
`P418-P424
`Nuclear cardiology/Magnetic resonance imaging and cardiac radiology. .....-.. eee e eee eee e teeters
`52
`P425
`Computers in cardiology ©... 2.60.60. eect e cece eee nen ee ete ee eee eee EEE EEE 53
`P426-P441
` Echocardiography/Doppler......... 2.6000 0c beeen renner eee eee EEE EEE EEE
`54
`P442-P449
`ModeratedPoster session I: Arterial hypertension ........ eee eee eee terete een nent nee ress
`58
`P450-P466
`Atrial fibrillation. ......0. 000 e cece eee eee nr EEE EEE EEE EEE EEE ETE EE
`60
`P467-P498 Mechanisms of arrhythmias. ....... 66.60 e cece eee teeter eee nee eee EEE EEE EE TEESE
`64
`P499-P540_—_Heartfailure: clinical aspects... 0.0.0 0.ce eee escent nner renee eee eee eee eee eee EEE 71
`P541-P558
`Pulmonarycirculation ..........0ee cece enceee EEE EEE EEE EEE EEE TEESE SS
`81
`P559-P606
` Thrombosis.........c000cc cence eter ener ee eee reer eee ee EERE SERRE TEESE REET TEESE TESS
`86
`P607-P623
`Coronary plaque imaging .....-.- +... sse reeset eee nee nent ene neeee 98
`P624-P652
`Endothelial function........-.. 0: eeeeee eee eee eee ener reese ester ees sere seer eee eee ees
`102
`P653-P682 Myocardial disease... . 6... veneer eee eee eee nee ne ee eee EEE EEE EEE EET 109
`683-686
`Computed tomography: Imagingof coronary ALLETICS . 0c cee cee enn en Een EEE enn een ee
`116
`688-691
`Young Investigators’ Award Session — Basic Science........ +++ +-+20sse0reteteesen nesses ee eereeese esses:
`117
`693-696
`YoungInvestigators’ Award Session — Thrombosis .......++ 0+ +++ 20ssecr rete n eres reese sere nee reer se sees
`118
`698-701
`Young Investigators’ Award Session — Population Sciences ......-+-.+++++-ssererrrenteseeresesseneee esses sss:
`119
`703-706
`Young Investigators’ Award Session — Clinical Science... ....+- ++. 20. sesertrr eee tes esses ees ee senses esses ss 120
`729-734
`New preventionstrategies 0.0... ..000ee ences eee e renee ee EEE EEE EEE EEE 121
`735-740
`Women, men and cardiovascular disease... 6.1.0 ee eee eee e reer eee t nent n eee ee eee ee eee 123
`741-746
`Multiple uses of myocardial deformation assessment by echocardiography ...... sss cece cree e eee eee tenner ees
`124
`
`
`
`Liquidia's Exhibit 1091
`Page 2
`
`Liquidia's Exhibit 1091
`Page 2
`
`

`

`xit
`
`Contents
`
`
`Communication in vascular smooth muscle cells... 2... ee eeeeceeeeeeseeeeveccseeveseveeeecce cc 126
`747-752
`Oxidativestress and the endothelium... 00... eel cetettetetreterteeeee 127
`767-772
`Improvingrisk stratification by nuclear CATIOlOgy. ... 0... eee eee ec ees eseseececaeceetaseuteceesecccsc
`129
`794-799
`Pathophysiological aspects ofresynchronisation therapy i... 6.0.0.0... cece eeccceeeesesaeseuessunccescecew
`130
`817-822
`Determinants and prevention of post myocardial infarctionleft ventricular remodelling...............0eecec ese,
`132
`823-828
`Ablation of atrial fibrillation: from source to SUCCESS... eee cee eeee etereS 133
`831-836
`Heart failure with preserved systolic function: whats EW? civiscive cs eetesesuewn eet éascmuevenstseisivuittecseces.
`135
`846-851
`Diagnosis and evaluation of heart failure — still a challenge in the everydayclinical Practice... eee 136
`852-857
`Noveltherapeutic strategies in chronic stable ANNA ieee eee crete te ee cece cence.
`138
`876-880
`Dilated cardiomyopathy or viral myocarditis? 0.0... eect eeeter 139
`913-918
`P955-P960 Moderatede-PostersII: Brugada syndrome 0024.0... .sseeesvasessessssseeeeessreeserstsererecccsscce ee 141
`PoolP976
`Atherosclerosis I~ Basic Science... eeeeeeeeeete ccs ceceeeens 142
`P977-P983
`Nuclear cardiology/Magnetic resonance imaging andcardiac tadiology.... 2... eee e ec ccc ccc ceceee eee
`146
`P984—P985
`Computersin OAPGUOIOBY ...++.+++0evnanniensteterersssvevnnitensestesesnewersisvenrtneiyeccccc
`147
`P986-P1000 EchocardioBraphy/Doppler.........eevevcssieereseeeeeescsssessseaesvnssesseetntees cc 148
`THORee, Ailisrosclerosls I= Besio\Sctames —wceses 4x1svsstdmeneness;sniniindaiierescloocnssssnne
`152
`P1017-P1023 Nuclear cardiology/magnetic resonance imaging and cardiac TadiolOgy... 6... eee cece cee eeeeevecee,
`156
`P1024-P1025 Computers in CARHOLOSY’s swnsisistisnnes essen vay epuainainissereesevuvinnee4tiviabaiuinnseresergnmmmmesesc
`157
`P1026-P1039 EchocardiographyOUPPl caecricece++s++asyetteioesdt4i++a senmnregitb)4abimmeisesssscccanece
`158
`P1040-P1047 ModeratedPoster session II: Exerciseoe 161
`P1048-P1076
`Implantable cardioverter-defibrillatoree 163
`PiO77-P1096 Ventricular tachycardia... seeecececceceeeesenete tte te etree treeens 170
`P1097-P1148 Heart failure: experimental aspects and risk of inflammation 0.6.0.2... 6... eee ce eec eee ece ccc ceeeeeeeec
`175
`P1149-P1196
`Ischaemia basic BSPOCS wih eso enn s eve sip gniemNied SAEs ons anrarrene eH 44d RAAiRUAe Os UAweaRRiR £14E44s omesces
`188
`Eee1225 Non-coronary interventions «25.00.6000. scecceceeceeeecetescesterteneeree ree eeegE 199
`PY226-P1254 Hypertension... . 2... eee eeeeeeete tee e erect tater tereteTs 206
`P1255-P1276 Valve SURELY wenn nes oes eraisvinaieiied nes asessyawnnensiens {Ei ess anmnnnneedasseauseks inaesoememrpeasesss,,,,
`213
`1277-1280
`Aortic interventions 2.2.0... seeeeeseceesceccee recat catcatesereveeretn eseEN 218
`Day 3 — Monday30 August 2004
`1300-1305—Endothelial function, oxidative stress and nitric Oxide... o.oo eee cceteretttreeeeeeeceeeecc 223
`1306-1310
`Gene expression,contractile function and hypertrophy .... 2... eee ee ceeteseeneeusesesecececesce,
`224
`
`1312-1317__Physicalfitness: correlations and Aeterminants .....cecceee esses suntvenesesscsveedeetstastibenseunecesccc.., 225
`1318-1323
`Percutaneousinterventions in congenital heart disease 00.0.6... ec ec ec eseesa eeu ceeeeeee 227
`1337-1342 Myocardial perfusion during acute ischaemia: the added value of myocardial contrast
`echocardiography (MCE) ...-......00..seteseeseceeeeceneeeeeeteccccutsreeeteetessevevtneeeeecc
`228
`1343-1348
`New aspects of endothelial function related to atherosclerosis... 0.0... e eee cece ceeeeeveceseecececccee.
`230
`1353-1358 Markers andidentification of the vulnerable Plaque... eee ee cece ee eee bese eeerec 231
`1369-1374
`Protection against ischaemia and ischaemia-reperfusion UNJUTYeee iee cece cece ec eee ccc 233
`1375-1380
`Frequent unwanted companions: hypertension and hyperlipidaemia... 00.2... .0. 0. cee ceeeeceecececcecee.
`234
`:
`1381-1386
`New horizonsin risk stratification of unstable Coronary Syndromes... 2.0... eee ccc cece eee cceececees
`236
`i
`
`
`| 1399-1403_Resistanceto antiplatelet BBOUS menue eet e EAHA RAknannoenaee ys $4 DEES Jobe + enamuben sy sh $4 ¥euReMIenecsoss 237
`1405-1410
`Intensive treatmentfor diabetes: key to improved prognosis... 0.00.0... ccc cececeececeeseeeueecececeeeeee,
`238
`1411-1416
`Oral treatment in prevention of in-stent restenosis 0.0.2.6... .660cccecssstevtstttevereeeee cee 240
`1425-1430
`Atrial fibrillation — clinical presentation risk factors and prognosis ................0e0ececeeeeeeeeeeceeecc
`242
`
`1458-1463__Risk stratification tools in the prediction of coronary events.........0. 00.0.2 0 ccc eceeceeeeeeeeeeteecencec.. 243
`1469-1474
`Statins in heart failure: friend or £007... .......csccsssececeeesssccsceusscenseeecrcccerece eee TES 244
`
`1475-1480—Betablockade: new aspects in chronic heart failure... 6... eee cee ecceeeeeeeteeeseeesecc 246
`
`1496-1501—Primary percutaneous coronary intervention — special issues ....... 0.00.6. eee eee ee eee eeee eee seeeececcc. 248
`1502-1507
`Evolving conceptsin the managementofaortic stenosis..... 6.6.0.6. cece cece e cee ec este ee eutesecececccc..
`249
`1512-1517
`Registries and guidelinesin acute Coronary SyNdFOMES.. 2... eee cece c eee e ee tueeeseeeeeccc ce.
`251
`P1544-P1559 Angiogenic andstemcell therapy — Basic Science 0... eee cece ese eeeeeeeeteeeeeececcc
`252
`P1560-P1566 Nuclear cardiology/Magnetic resonance imaging and cardiac radiology ...........6..0.0. ccc eeeeeececcececece.
`256
`P1567-P1568 Computers in CAPGIOLOSY ss eeeee sees eeeveesuennneeessceesevseensesessaunesessuessssaneeeesentereccccc
`258
`P1569-P1583 Echocardiography/Doppler............0000cececeeeeceteeetttttttee tees tet t tet tttt 258
`
`P1584-P1598 Angiogenic and stem cell therapy — Basic Science 00.0... eee cee cece cee ect eee esse eteceeeecc co.
`262
`P1599-P1606 Nuclear cardiology/Magnetic resonance imaging and cardiac radiology ...........0.00 00. cc cece ee eeeceeeeccece.
`266
`P1607-P1608 Computers in CATMIOLOSY «0. ieee eevee eee eee eee eeeeeses eect eseaeesessereseuseteeeeaesiee sees cc, 268
`P1609-P1623 Echocardiography/Doppler.........0.....00ceccceeseteeesteteeseeteeetttntrt ettercn 268
`P1624-P1631 Moderated Poster session Ill: Catheter ablation... 2.0... 0. eecectverteeeeetee 272
`PLO32-P1G65 Catheter ablation.....6....66 ss eecseeeeseeeeeeeseeeccnaeecesteerietersereee cre ee EES 274
`
`
`
`
`
`Liquidia's Exhibit 1091
`Page 3
`
`Liquidia's Exhibit 1091
`Page 3
`
`

`

`tgmg
`SS
`
`Contents
`
`xiii
`
`P1666-P1709
`P1710-P1766
`P1767-P1811
`P1812-P1826
`P1827-P 1844
`P1845-P 1871
`1872-1875
`1929-1934
`1935-1940
`1941-1945
`1947-1952
`1961-1966
`1967-1972
`1973-1978
`1989-1994
`1995-2000
`2001-2006
`2007-2012
`2026-203 1
`2032-2037
`2042-2047
`2052-2057
`2087-2091
`2097-2102
`2107-2112
`2113-2117
`2119-2123
`2129-2134
`2140-2145
`P2166—P2178
`P2179-P2185
`P2186
`P2187-P2201
`P2202-P2213
`P2214—P2220
`P2221—P2222
`P2223-P2237
`P2238-P2245
`P2246-P2265
`P2266-P2286
`P2287-P2341
`P2342—P2409
`P2410-P2438
`P2439-P2484
`2485-2488
`
`Peptides and heart failure .... 0... cece cece nen ne EERE TENE EE EEE EEE Ee EEE Eee nen ES
`Acute coromary SYMGrOMeS . 1... cece cece cece eee tenet teen e teensegoheotilr NB 464 Silbsoursame «
`0
`©
`6
`«
`» oxssncenmeneexerss:
`«
`«
`«
`Percutaneous coronary intervention .. 0... cee eee eee e eee een nee E net eee e eee eas
`NUTSIE... 6. wninseseererene ies 4984 AAG aAITIRGNENS FENET EEF 8
`A AGUIRIOINS T E494 6 FATIMRITIR RS #8 Yd 4 DERTNUIINETUS os 00 9» eanseuesemeronnanen we
`Exercise'testingiand rehabilitation. «<i iss5 swmwnosmme ees sass emeore ee is 99 sot MENT ae ts puMmONW FEED Daa ea TAawS
`Hypertension therapeutic aspects : ....s ensessaemwes oes ya a eenmemae excess ao aremmne des a4 s aemennns Fane d o¥ se wae
`Advanced cardiac imaging « .. 55: sessnsseur cece ees 09 4 ereneene ded be ee wnmteee Heed oeMONO CN er ee AwUur TOOT Ye
`Bio-markers of cardiovascular GiS@ASe «.. 6. ices sewwenene cece ewe enewe rere bev meweee tenes oea ewRTOEE ES Fe eE OSES
`
`Novel magnetic resonance techniques to assess coronary artery disease ......... ce cee cece ete eee nner e eee ee
`Mechanisinis tinderlying plaque instabity o.oo es sce e secsrewrncee vee sew nietnseieee oa evs eueleremnimene eee EE Sa SERI ROO E He
`Hormonesand cardiac fUnction ..... 6. cc ene een e eee E ee eee ene ene eee nee eens
`
`282
`292
`306
`317
`321
`325
`332
`333
`
`334
`336
`337
`
`339
`Clinical and genetic aspects of arrhythmias ........ 0.06... cece cnn nr nee enn treet nes
`340
`Recent advancesin three-dimensional echocardiography ......... 6 cece cece ce eee teen eee eee ene e nea
`342
`Ischaemia-reperfusion, slow flow and no reflow .... 20... ccc ec cc eet e eee e cette eter enen ees
`343
`Computer-based advances in cardiology ....... 0... cececen enn net e nr e eens
`345
`Vascular and myocardial damage and remodelling ......... 2.00.2 cece cece cence ence nee eee
`346
`Subclinical peripheral artery disease: a marker for severity of coronary artery disease .................00...0005.
`348
`Stem.cells in. heart failutes saan soos v3.2 oa oeauememe ss oss ¢6 SON He Tes £3 sem He Cet eS oe OREN Eds eee Roa
`349
`Percutaneous interventions in unstable coronary syndromes ........... 0... cece cence eee ene ee ences
`Neurally mediated syncope:a recurrent syndromerevisited... .... 2.0.2.0 cece eee cence eee tenes 351
`Novel pharmacological approaches for the treatmentofatrial fibrillation ........ 6.6... secs eee e cece eee tee ee ees
`352
`New developments in thrombolysis: fibrinolysis ............. 0 sce cece cee e cnet e erect eet etter n een ees
`354
`A newerain the prognostic assessmentof heart failure patients .......... 0... cece eee ee ce eee e eee enn e eines
`355
`New evidencefor the beneficial effects of exercise training ....... 6... eee cece ence terete eee enn eee e tees
`357
`Primary percutaneouscoronaryintervention in acute myocardial infarction..........se ese e cece eee nee ene nee
`358
`Manythings to remember in CABG... cece ene ent net E ene Eten nee EG
`360
`Exercise testing in mitral valve disease ........ cece cece cree een eee tere e tnt e teen eee tenet ent ete tees
`361
`Drugelutingstents in diabetic patients ..........:c ese ce eect eee teen nee tee e eect eterna ner nee nrsee ener eens
`362
`Bad and goOd Habits « css +s ineusmeierereve ne 9 eu 02 v 40 voemesaserninrer eae ma arerenacnenne ere +
`a
`inseipiinisunnin ana eae mceuatecenanacaseinus eo Es
`364
`Stress-induced myocardial damage and protective mechanisms — Basic Science. ............. eee cece eee e eee nee
`365
`Nuclear cardiology/MRI and cardiac radiology ....... 6s cece cece eee e terete eet nent n eee
`368
`Computers in cardiology... ccc cece cece e reer ee ne ete etter etre reenter ener e en en nnn
`370
`Echocardiography/Doppler..... 0.0... c cece EE EE EEE EEE EERE een EE EERE EEE 370
`Stress-induced myocardial damage and protective mechanisms ......... 6. cece eee cece eee e eee nee tenes
`374
`Nuclear cardiology/Magnetic resonance imaging and cardiac radiology ....... 66. e cece eee cece eee eee tee eees
`377
`Computers in cardiology ....... ccc cece eee eee cee rene eee e Ee ENE EEE EERE ELEN EERE EEE DEERE ECE D EE ee ES
`379
`Echocardiography/Doppler..... 0... cece cece ERE EEE EEE EEE E EEE EE EERE EEE EEE EEE EE
`379
`Moderated Poster session IV: Inflammation and coronary artery disease..... 6... cc cece cece eee eee cence eee
`383
`PACER 56. ccenessiarmen os soe se a nnesninwcnnmine eee aces be udiateld 22 5255 RMGMINSAE sao 4s adINWRINEE Ke ee a aaa getneEM eee
`385
`Mechanisms of arrhythmias......ccccccsss ss sss sncimmmnenn sree euumieuls dense es Maree Ee ee sa ae sOMNeeMNER EES Ee
`390
`Resynchronisation therapy ......... ccc cee cece ete nee eee ener ee eee e eee eee en eee ee tere Eten ene e ett E eee
`395
`Acute myocardial infarction and reperfusion therapy........ 0. cece eet eee t ener tener enn t ene n enn e ees
`408
`Coronary circulation: functional evaluation ....... 0... cece ee ere e ner e en een etree een een E Renn EE EEE Eee EE
`425
`Epidemiology svicsiess cx sie ss weiremanmees ¢
`6 ea ee ee ae etcenennineniete a eb ee ammmcnratninces oe 8 a obareunne gpeececeenne ©
`6 9 wae MYazeraceceuscasezece
`432
`Databases and guidelines. ......... ccc c eect ee nee en nen nee tenet n enter tenn ene n enone es
`443
`
`2605-2609
`2611-2616
`2617-2622
`2636-2641
`2642-2647
`2648-2653
`2667-2672
`2673-2677
`2709-2714
`2725-2730
`2768-2773
`2774-2779
`2799-2804
`P2830-P2835
`
`Day 4 — Tuesday31 August 2004
`Congenital heart disease: secondary challenges after early “repair” ...... 10.06 cece ences 447
`Experimental cell transplantation: preclinical and clinical developments ............ 6s cece eee cent eee eee eee
`448
`More‘fuel to inflammation wees sey es 4222s maemeter oe a5 5 ys emerewren sav es oe suena ee ee 8 an suecmenmeO ENC EES Os
`449
`Chronic heart failure: new treatment Options ....... 66 cece ec nnn ee eet e ene e eet e tenn nent teen aes
`451
`Oral anticoagulation foratrialfibrillation — still unresolved ...... 6... cece eee eect tent e eee enae
`452
`The diabetic VESSEL occ oe. 5 ee ee cetera on nee enlnldlanthdie dag N
`Ss RAWGWBIRRL EF a se GR ENR Heda oe a
`4 oe 454
`Heart failiive news from-off the beaten track... scaccsse ce cease sawn nays so 64 seas coe ese some Kenmore sees
`455
`Catheter ablation of ventricular tachycardia... . ccc cen nen en eee een n nen ete E ene eres
`457
`Diabetes and the heart «: i. 22 22 seesesewews cece es ee oeemmnee cee 62a 6 eases nee ae ee ewer PORE 8 88a 8 i eTtsee
`458
`Treatment and outcomeofacute pulmonary eMbOLISM ..... 6. cee eee teen ete eee 459
`Coronary artery disease and renal failure: prognostic aspects and prevention......... 6... .e eect e cette eee re ee ee ees
`461
`Clopidogrel loading — 600 mg may be better ..... 0... sce e cee eee een nee erent eens
`462
`Mitral regurgitation: from prognosis to treatMeNt ..... 6.6 cee eee eee eee ee een eee eens
`464
`Moderated e-Posters III: Drug therapy in cardiovascular disease. ..... 0... cece eee ene eens 465
`
`
`
`Liquidia's Exhibit 1091
`Page 4
`
`Liquidia's Exhibit 1091
`Page 4
`
`

`

`Contents
`xiv
`
`
`P2836-P2851
`P2852-P2858
`P2859
`P2860-P2874
`P2875-P2887
`P2888-P2894
`P2895-P2896
`P2897-P2911
`P2912-P2919
`P2920-P2950
`P2951-P2995
`P2996-P3046
`P3047-P3079
`P3080—P3123
`P3124—P3144
`3145-3148
`P3265-P3270
`P3271-P3284
`P3285-P3291
`P3292-P3293
`P3294—P3308
`P3309-P3323
`P3324-P3330
`P3331-P3332
`P3333-P3347
`P3348-P3354
`P3355-P3374
`P3375-P3394
`P3395-P3418
`P3419-P3444
`P3445—P3485
`P3486-P3512
`P3513—P3531
`P3532-P3544
`P3545-P3577
`P3578-P3588
`3589-3592
`
`3617-3622
`3627-3632
`3637-3642
`3643-3648
`3649-3654
`3655-3660
`3661-3666
`3671-3676
`3681-3686
`3687-3692
`3693-3698
`3703-3708
`3713-3718
`3723-3728
`3729-3734
`3735-3740
`3745-3750
`3751-3756
`3757-3762
`3763-3768
`3778-3783
`3784-3789
`
`467
`Endothelial function, vascular care and POMOMEMAR 5 sicmnaners 2444 pnuvsiname was sussinisihde neeeeeneveeweeec......
`Nuclear cardiology/Magnetic resonance imaging andcardiacLe 471
`FEtt SREUSIONY -sxcssosons sit ss -+pyssnice ee evmusamesticsroamenancenn nce 472
`Echocardiography/Doppler TEER TREC EE CEE Cee eee eneaE Osea eeneaeesageEeeevaaswueeedserees,
`473
`von channels and arrhythmias... ..-..+sesssssseeeteseeeesiseseesnencersere 476
`Nuclear cardiology/Magnetic resonance imaging and cardiac TAGIOLOBY 0. eee cece ee ec eeeseeeencecece.
`479
`amputersin cardiology s+... es eesesecseseeeeeteeesiseeente cies cere eees 481
`eenocardiography/DOPDIer.«. os. eeseseeeieteee tess isnsatoceteesnee 482
`Moderated Postersession V:Trials in heart PANUB i witiene o> sev sures sbasessauncnabedttes sonemenmnecscrcs
`485
`RET ADEMRHOM «esses sseesseeeeseaseseeieaneseseecsasacnutientecesenecee ceEE 488
`eatt failure: clinical aspects... sees esses ese tsesnseeentete nieceer 495
`Coronaryartery diseasein igh-tisk patients «0.0.0.0... eesecesceseeeeteetsstserimecn eee 506
`Restenosis and Grug-elUting SteMtS 6 eect eecteect 519
`Men tt tithe cess esesenenninisacesesessattantieenssitasanticusiorcrerenet 527
`BnPASE 8 omnentt 4548123 onsnnnys at S7Fi ommnsgtitdttidnmnnetramen 537
`Simulation and modelling .......++..e+sseeeveeessetesseteneeesen cree cece ee es 543
`Moderatede-Posters IV: Nurse-led interventions in patients with heart failure... 544
`Cardiac hypertrophy and remodelling contractile function — Basic Science... cece eee,
`545
`Nuclear cardiology/Magnetic resonance imaging and cardiac THMOLOZY a onions 0245+ vipitiisneneseis$44scyiebineees
`548
`Computers in CaTCHOLOBY«vee sees eee eect cette teen e ttt t eet cet et ti ttre ee EE 550
`Echocardiography/DopplerNT, LURES PEER ERs caeneng b 81455 kunnen das) SDD DIROOws vot g gi eu HEE.
`351
`Cardiac hypertrophy and remodelling contractile function — Basic Science............0.cc.00 554
`Nuclear cardiology/Magnetic resonance imaging and cardiac radiology©... cece ccc ce eee ee,
`558
`Computers in CaGIOLOBY «eee sere e esses ee ei eet ee taeee cette tee tate ttn tiec er TEES 560
`SBPLYIDOBBIE wonascicne stirs. «+ nomexoies t41+ 04 enna sitivivinbooonssccen 560
`Moderated Poster session VI:In stent POSEEDOBIS..-svevyinaiinn OUidscneneewny sé} 4ubsnmunmeety situate...
`564
`SeOCRRCOBTEHY ooo esse eects eee teee tata tee tatters tereercre ee ss 566
`SYNGODCs «oes svvwenesssestireeeeseenenetseitttsseentuensitatisnrmrresisceee ant 571
`spear transplantation «sss sssseetesseeesessssersasesansserssersetsssrrseersrersreree 575
`Heart failure — medical MNETEPY vere ete tetera e tite ce tent tie 581
`Nabvalat GUBGHRE £55 soncowones 4142555 inneumoranpseds¥ibnenncenttsghsdatibinhsoscscneeee
`588
`Coronaryartery disease:risk stratification and medical therapy... 0... eeeecccceeee ee.
`597
`SHOKDsooo oavnees erssenssersneeescareecseseteeaeteeutssstitatetertircererireerie ere et 604
`ercise testing and rehabilitation... ee eeee teeter reecers 608
`Crown-up and congenital heart disease. ....seeeeeeee eee ecteerrer rere 611
`Coronaryartery bypass BTHAIDBsso. e sees eisteeeeneesssesteeeeatesssatetiitnecec 620
`DRADEBES ooo esses teseseseieseeesccestscseetrtttntanasssssisievicissterereeterreersn ene 622
`Day 5 — Wednesday1 September 2004
`627
`FnMIS «ses oneness nsse4 its anmmsnae (eesti ss acumen sstssaveaunevessuraemapeuneivesrescosece
`628
`Structure and function of cardiac ion ChaMNels. «o.oo ee eeeeneseneetessseeeseeestssasteneecce
`Lipid modulation in atherogenesis ~ beyond cholesterol... 20... 0... eeeeeceeeeveeeereeeee 630
`Pulse pressure, distensibility and cardiovascular tisk... 0.0.06... eeeeecceee cere eee 631
`Fat, lean or active: all relevant for cardiovascular tisk? ..... 0... seecceececeseceeeeseuuecereessunerecc ce,
`633
`Conductionofthe electrical EMDUIRE 55 nannmeneneve 2144 Fotcewmnmes ¥ 1485 AAtasinn vel svsaypymater snc 634
`Novelplayers in receptor-mediated signalling in cardiac MYOCYTES oe eee eee cree ee,
`636
`‘nctear cardiology ~ beyond the future... eet tetetite rere 637
`pnalenges in aortic interventions...........6.csescesecceesseenecsenererenenece eee eeEe 638
`Stenting of supra-aortic extracranial arteries 0... .6.0. oes eeteteceereee 640
`Newnavigation and mapping techniques for targeting the arrhythmogenic substrate............0. 00... 000000.
`641
`Reducing thromboticrisk — old COMBEPES, HOW TROPSs 22... eucrmcrie 6444495 bhinvonlon ny e404 p4ieginwees veces
`643
`Acute myocardial intervention and diabetes... 06.0.0... ee eee cetteetee reer 644
`racing mode and lead position: does it matter? 2.2... eee c eee rereeS 646
`How importantis abnormal respiration in heart failure? ...... oe seeeeeeeeceeeeeeteeces ccc ee 647
`Newinsights into native or Repaired aiiteal walYedymamites’ ... « vpsscuas 24) ths onnmoesneeest43i4idmemmess.,..,,
`649
`Renal dysfunction and anaemia — overlooked parts of the heartfailure syndrome. ...... 00.00.00. 0. ccc cee eee ee 650
`Ablation ofatrial fibrillation: new tOCHMIGUES «0661s eecvsenece csv esevsntatadesesecuunensatedsstsecssccse,,
`652
`Management Of aonte heart failute..n.c+ss+s+sesereneitusasessearenenetsticeneecncccccc
`653
`Multiple applications of cardiac computed tomography ...... 00.2.6... oe eteeeseeseseeeeseee eres esc,
`654
`Challengingissues after valve HOPIACEHIEHE, wascasinsines cv osey panne 6445400 vemennduys¢4nianmmenntessecas,.,
`656
`Clinical assessment of resynchronisation CREED <1 22 15% bamnomnsonn ss 1 85 4 giRidine 9» oa amergninia £9 ¥en eoseocce,
`658
`
`
`
`Liquidia's Exhibit 1091
`Page 5
`
`Liquidia's Exhibit 1091
`Page 5
`
`

`

`
`
`Contents
`
`xv
`
`660
`Hypertension andheart failure... 2.0.0... cece cece en en eee Eee ene eee eee ee
`3790-3795
`661
`Blood pressure reduction and cardiovascular risk ...... 1.6... es eceee ee eee eee e eee e enter nee ene e es
`3801-3806
`Heart CCOMOMICS 0... cece ee ee EE EEE REET EE EEE EEE EE EEE SEE EE EEE EEE EEE 663
`3811-3816
`Physical training and secondary prevention .......... 2.0... see eee eee eee eee etn ener n es
`664
`3821-3826
`Percutaneous coronary interventions in diabetic patients.......... 06... sec e cece eee eee eee n nes 666
`3827-3831
`Prognostic value of stress echocardiography ......... 066.222. e see eee ener t teeter eee n enn es
`667
`3833-3838
`
`3839-3843—Restenosis following bare Stents 0.0... 0... c cece cece eee ener ne rene eee e tener enn e eats 669
`3845-3850
`Drug elutingstentto treat in-stent restenosis ........ 0.0.62. 2 00sec cette eee eee een ner een e eens
`670
`
`Author Index 2.2.0.0... ccc ccc ce enn EEE EEE EEE ETE EEE EE EEE EC e EEE Eee eer e tenet nent tenes ns rees
`
`Indexof Topics .......... ccc cece eeeen ee nner enter nner ceeeece renner seeseeeeecsserrseen es
`
`673
`
`717
`
`Liquidia's Exhibit 1091
`Page 6
`
`Liquidia's Exhibit 1091
`Page 6
`
`

`

`22
`
`
`
`month for a period of six months. The parameters studied were the pulmonary
`artery systolic pressure (PASP)bytricuspid regurgitation (TR) jet and pulmonary
`artery diastolic pressure (PADP) by pulmonary regurgitation (PR)jet.
`Results: Mean age of the subjects was 42.6-9.3 years. Twenty seven (90%)
`were females and 3 (10%) were males, Sildenafil was well tolerated and there
`
`Sildenafil in the treatmentof primary pulmonary
`hypertension
`A. Dharmadhikari', M. Kulkarni?, V. Tzifos3, F. Airoldi*, |. Sheiban§,
`™Nashik, India; ?Rajebahadur Heart Foundation, Cardiology, Nashik,
`India; Hospital Hunry Dununt, Interventional Cardiology, Athens,
`Greece; “Hospital San Raffaele, Interventional Cardiology, Milano, Italy;
`University Hospital, Torino, Interventional Cardiology, Torino, Italy
`Backgroud:Therole of sildenafil as a pulmonary vasodilatoris being extensively
`evaluatedin the treatmentof pulmonary hypertension,
`Aim: This was a Prospective study to assess the benefit of adding sildenafil in
`Patients with high pulmonary artery pressures secondary to atrial septal defect
`(ASD), already receiving the conventional therapy.
`Methods:Thirtyconsecutive Patients with moderate to severe primarypulmonary
`hypertension were included in this study, All the patients were diagnosed previ-
`ously and were receiving the conventional therapy with digoxin, diuretic and a
`
`Epidemiology andtreatment ofpulmonary arterial hypertension/TheECG andelectrophysiologic markers ofarrhythmic events
`Inhaled treprostinil is a potent pulmonaryvasodilatorin
`severe pulmonary hypertension
`R. Voswinckel, M.G. Kohstall, B. Enke, T. Gessler, F. Reichenberger,
`H.A. Ghofrani, W. Seeger, H. Olschewski. Medical Clinic 2, Department
`ofInternal Medicine, Giessen, Germany
`Background: Treprostinil has been approved for
`therapy of PAH (US and
`Canada) as continuous subcutaneous infusion. However,
`local pain at the infu-
`sion site is a major drawback. Inhaled therapy with another stable prostacyclin
`analogue(iloprost) has been approved for PPH (EMEA).In this study weinvesti-
`gated the acute hemodynamic responsetoinhaledtreprostinil.
`Methods: Open-label, single blind placebo-controlled clinical study. After place-
`ment of a Swan-Ganz catheter and a femoral arteryline, patients inhaled solvent
`solution (placebo) (n=8) or treprostinil for 6 min (OptiNeb ultrasound nebulizer,
`Nebu-tee, Germany)in concentrations of 16, 32, 48, and 64 g/ml (n=6, 6, 6, and
`3 patients). Measurement was performedbefore andafter 0, 15, 30, 60, 90, 120,
`150 and 180 min. The mean area between the placebo andthe treprostinil curves
`(ABC186) was calculated (baseline=100%).
`Results: We investigated idiopathic PAH (n=10), collagen vascular disease (n=5),
`chronic thromboembolic disease (n=9), and pulmonaryfibrosis (n=5), f/m = 19/10,
`age 56 + 3 years, PAP PAWP, and CVP 51.3 + 2.2,9.2 + 0.8, and6.6+0.6
`mmHg, CO 4.4 + 0.3 Vmin, SvO2 62.3 + 1.2%, PVR 885 + 72 dyn s cm’,
`At 16.g/ml there were no significant adverse events, Headache, cough or bron-
`choconstriction were observed in 2, 1, and 2 patients at 32, 48, and 64 jg/mi.
`These were mild andtransientin all patients but one (64 g/ml) who complained
`of major headachefor 1 hour. Placeboinhalation wasfollowed by slowly increas-
`ing PVR. Compared to this, the maximum treprostinil effect was reached after
`about 50 min andhalf-maximal effects at about 110 min. The ABC186 for PVR
`Was —24.7 + 4.4, -28.7 + 4.9, and -29.0 + 4.7%; PAP -14.4 + 3.3, -13,5 + 5.2,
`713.1 + 2.6%; SAP -5.1 + 3.0, -6.0 + 3.1, -3.8 + 2.1% at 16, 32 and 48 g/ml.
`Conclusion: Treprostinil inhalation results in a significant long-lasting pulmonary
`vasodilatation. With the applied technology, at a Concentration of 16\.9/ml, near
`maximal pulmonaryvasodilatation is achieved without adverseeffects. At higher
`doses, local and systemic side effects may occur, whereas pulmonary selectivity
`is preserved.
`This study was supported by Lung Rx.
`
`withdrawlof the drug. Twopatients died during the follow-up period. At the begin-
`ning of the therapy, 22 (73.3%)patients were in NYHAClassIII or IV while at the
`end of six months, only 8 patients remainedin either of these classes (p<0.05).
`By the 6 min walk test, functional Capacity improved from 181.54122.4 meters
`to 302.74150.3 meters P(<0.05). Modified Borg dyspnea score improved from
`§.641.2 to 3.34141 (p<0.05). PASP by TR jet (mmHg) was down from 81 -3414,7
`to 51.4411.7 (p<0.05). PADP by PRjet (mmHg) reduced from 56.2+11.7 to
`33.4£9.1 (p<0.05).
`Conclusion: Sildenafil is well tolerated, improves symptoms, and reduces the
`systolic and diastolic pulmonaryartery pressures in patients with moderate to
`severe primary pulmonaryarterial hypertension.
`
`The endothelin-receptor antagonist bosentanfor the
`treatmentof pulmonaryarterial hypertension associated
`with congenital heart defects
`O. Sitbon', M, Beghetti2, J. Petit, L. Iserin*, M. Humbert!, V, Gressin$,
`G. Simonneau'. *Hépital A